MDT · 10-Q · 2026Q3 · Full report

Neuroscience Product Adoption

Medtronic plc · 2026-09-03 · Importance 54 · Surprise 40 · No source text

Neuroscience sales grew 10%, with Cranial & Spinal Technologies up 13% on continued adoption of the AiBLE ecosystem, Core Spine, and Neurosurgery. Specialty Therapies increased 10%, driven by Altaviva, ENT, Neurovascular, Scientia-related products, and Flow Diversion, partly offset by the Pipeline Vantage recall. Neuromodulation grew 5%, supported by Pain Stim and the Percept RC neurostimulator with BrainSense technology. The company expects further adoption of AiBLE, Stealth AXiS, spinal enabling technologies, stroke devices, Pelvic Health therapies, spinal cord stimulation, and BrainSense deep-brain stimulation.

Key facts

• Neuroscience net sales for the three months ended July 31, 2026 were $2,678 million compared to $2,427 million for the three months ended July 25, 2025, an increase of 10 percent. source
• Cranial & Spinal Technologies net sales for the three months ended July 31, 2026 increased 13 percent compared to the corresponding period in the prior fiscal year. source
• Specialty Therapies net sales for the three months ended July 31, 2026 increased 10 percent compared to the corresponding period in the prior fiscal year. source
• Neuromodulation net sales for the three months ended July 31, 2026 increased 5 percent compared to the corresponding period in the prior fiscal year. source

Impact estimates